Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model
Better delivery systems are needed for routinely used vaccines, to improve vaccine uptake. Many vaccines contain alum or alum based adjuvants. Here we investigate a novel dry-coated densely-packed micro-projection array skin patch (Nanopatch™) as an alternate delivery system to intramuscular injecti...
Gespeichert in:
| Veröffentlicht in: | PloS one 2010-10, Vol.5 (10), p.e13460-e13460 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e13460 |
|---|---|
| container_issue | 10 |
| container_start_page | e13460 |
| container_title | PloS one |
| container_volume | 5 |
| creator | Corbett, Holly J Fernando, Germain J P Chen, Xianfeng Frazer, Ian H Kendall, Mark A F |
| description | Better delivery systems are needed for routinely used vaccines, to improve vaccine uptake. Many vaccines contain alum or alum based adjuvants. Here we investigate a novel dry-coated densely-packed micro-projection array skin patch (Nanopatch™) as an alternate delivery system to intramuscular injection for delivering an alum adjuvanted human papillomavirus (HPV) vaccine (Gardasil®) commonly used as a prophylactic vaccine against cervical cancer.
Micro-projection arrays dry-coated with vaccine material (Gardasil®) delivered to C57BL/6 mouse ear skin released vaccine within 5 minutes. To assess vaccine immunogenicity, doses of corresponding to HPV-16 component of the vaccine between 0.43 ± 0.084 ng and 300 ± 120 ng (mean ± SD) were administered to mice at day 0 and day 14. A dose of 55 ± 6.0 ng delivered intracutaneously by micro-projection array was sufficient to produce a maximal virus neutralizing serum antibody response at day 28 post vaccination. Neutralizing antibody titres were sustained out to 16 weeks post vaccination, and, for comparable doses of vaccine, somewhat higher titres were observed with intracutaneous patch delivery than with intramuscular delivery with the needle and syringe at this time point.
Use of dry micro-projection arrays (Nanopatch™) has the potential to overcome the need for a vaccine cold chain for common vaccines currently delivered by needle and syringe, and to reduce risk of needle-stick injury and vaccine avoidance due to the fear of the needle especially among children. |
| doi_str_mv | 10.1371/journal.pone.0013460 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1292197689</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A473853876</galeid><doaj_id>oai_doaj_org_article_7f32d55947544ab2a2594dfda5c74e29</doaj_id><sourcerecordid>A473853876</sourcerecordid><originalsourceid>FETCH-LOGICAL-c723t-2df7293f5484011852cd2f1197491ed7458f6ce06fb699b63b5df27abc1eb2783</originalsourceid><addsrcrecordid>eNqNk12L1DAUhoso7rr6D0QDguLFjPlok_ZGWBY_FhYWXPU2nKbpTMY0qUk7uhf-d1Onu8zIglJoD8lz3jTvOSfLnhK8JEyQNxs_Bgd22XunlxgTlnN8LzsmFaMLTjG7vxcfZY9i3GBcsJLzh9kRxZXghPHj7NfVN-PQFpQyDgbjHYIVGBcHpHTYGgUWKXApRhCjVwYG3aD12IFDPfTGWt_B1oQxoh9mWCNAzm-1RZ1RwS_64Dda7VRDgGuUjgLU-THq9G60fZw9aMFG_WT-nmRf3r_7fPZxcXH54fzs9GKhBGXDgjatoBVri7zMMSFlQVVDW0IqkVdENyIvypYrjXlb86qqOauLpqUCakV0TUXJTrLnO93e-ihn56IktKJJhJdVIs53RONhI_tgOgjX0oORfxZ8WEkIg1FWS9Ey2hRFlYsiz6GmQFPctA0USuSaTlpv59PGutON0m4IYA9ED3ecWcuV30paFZyzSeDVLBD891HHQXYmKm0tOJ3Mk6XIU2mr5M2_SMExJZgVk-aLv8i7bZipFaSbGtf69INq0pSnuWBlaiDBE7W8g0pPo1PhUz-2Jq0fJLw-SEjMoH8OKxhjlOdXn_6fvfx6yL7cY9ca7LCO3o5Ty8VDMN-BqS1jDLq9rQbBchqnGzfkNE5yHqeU9my_krdJN_PDfgPgXhug</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1292197689</pqid></control><display><type>article</type><title>Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Corbett, Holly J ; Fernando, Germain J P ; Chen, Xianfeng ; Frazer, Ian H ; Kendall, Mark A F</creator><creatorcontrib>Corbett, Holly J ; Fernando, Germain J P ; Chen, Xianfeng ; Frazer, Ian H ; Kendall, Mark A F</creatorcontrib><description>Better delivery systems are needed for routinely used vaccines, to improve vaccine uptake. Many vaccines contain alum or alum based adjuvants. Here we investigate a novel dry-coated densely-packed micro-projection array skin patch (Nanopatch™) as an alternate delivery system to intramuscular injection for delivering an alum adjuvanted human papillomavirus (HPV) vaccine (Gardasil®) commonly used as a prophylactic vaccine against cervical cancer.
Micro-projection arrays dry-coated with vaccine material (Gardasil®) delivered to C57BL/6 mouse ear skin released vaccine within 5 minutes. To assess vaccine immunogenicity, doses of corresponding to HPV-16 component of the vaccine between 0.43 ± 0.084 ng and 300 ± 120 ng (mean ± SD) were administered to mice at day 0 and day 14. A dose of 55 ± 6.0 ng delivered intracutaneously by micro-projection array was sufficient to produce a maximal virus neutralizing serum antibody response at day 28 post vaccination. Neutralizing antibody titres were sustained out to 16 weeks post vaccination, and, for comparable doses of vaccine, somewhat higher titres were observed with intracutaneous patch delivery than with intramuscular delivery with the needle and syringe at this time point.
Use of dry micro-projection arrays (Nanopatch™) has the potential to overcome the need for a vaccine cold chain for common vaccines currently delivered by needle and syringe, and to reduce risk of needle-stick injury and vaccine avoidance due to the fear of the needle especially among children.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0013460</identifier><identifier>PMID: 20976136</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adjuvants ; Alphapapillomavirus - immunology ; Alum ; Aluminum ; Aluminum sulfate ; Anaphylaxis ; Animals ; Antibody response ; Antigens ; Bioengineering ; Biotechnology/Bioengineering ; Cancer ; Cancer vaccines ; Cervical cancer ; Cervix ; Children ; Dose-Response Relationship, Immunologic ; Drug delivery systems ; Drug dosages ; Ear ; Fear & phobias ; Female ; Health risks ; Hostages ; House mouse ; Human papillomavirus ; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 ; Immunogenicity ; Immunoglobulins ; Infectious Diseases/Sexually Transmitted Diseases ; Influenza ; Injury prevention ; Medical research ; Mice ; Mice, Inbred C57BL ; Microscopy, Electron, Scanning ; Models, Animal ; Nanotechnology ; Neutralizing ; Papillomavirus ; Papillomavirus Vaccines - administration & dosage ; Projection ; Risk reduction ; Skin ; Skin - immunology ; Uterine Cervical Neoplasms - prevention & control ; Vaccination ; Vaccines ; Virology/Vaccines ; Viruses ; Women's Health/Gynecological Cancers</subject><ispartof>PloS one, 2010-10, Vol.5 (10), p.e13460-e13460</ispartof><rights>COPYRIGHT 2010 Public Library of Science</rights><rights>2010 Corbett et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Corbett et al. 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c723t-2df7293f5484011852cd2f1197491ed7458f6ce06fb699b63b5df27abc1eb2783</citedby><cites>FETCH-LOGICAL-c723t-2df7293f5484011852cd2f1197491ed7458f6ce06fb699b63b5df27abc1eb2783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956639/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956639/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20976136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Corbett, Holly J</creatorcontrib><creatorcontrib>Fernando, Germain J P</creatorcontrib><creatorcontrib>Chen, Xianfeng</creatorcontrib><creatorcontrib>Frazer, Ian H</creatorcontrib><creatorcontrib>Kendall, Mark A F</creatorcontrib><title>Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Better delivery systems are needed for routinely used vaccines, to improve vaccine uptake. Many vaccines contain alum or alum based adjuvants. Here we investigate a novel dry-coated densely-packed micro-projection array skin patch (Nanopatch™) as an alternate delivery system to intramuscular injection for delivering an alum adjuvanted human papillomavirus (HPV) vaccine (Gardasil®) commonly used as a prophylactic vaccine against cervical cancer.
Micro-projection arrays dry-coated with vaccine material (Gardasil®) delivered to C57BL/6 mouse ear skin released vaccine within 5 minutes. To assess vaccine immunogenicity, doses of corresponding to HPV-16 component of the vaccine between 0.43 ± 0.084 ng and 300 ± 120 ng (mean ± SD) were administered to mice at day 0 and day 14. A dose of 55 ± 6.0 ng delivered intracutaneously by micro-projection array was sufficient to produce a maximal virus neutralizing serum antibody response at day 28 post vaccination. Neutralizing antibody titres were sustained out to 16 weeks post vaccination, and, for comparable doses of vaccine, somewhat higher titres were observed with intracutaneous patch delivery than with intramuscular delivery with the needle and syringe at this time point.
Use of dry micro-projection arrays (Nanopatch™) has the potential to overcome the need for a vaccine cold chain for common vaccines currently delivered by needle and syringe, and to reduce risk of needle-stick injury and vaccine avoidance due to the fear of the needle especially among children.</description><subject>Adjuvants</subject><subject>Alphapapillomavirus - immunology</subject><subject>Alum</subject><subject>Aluminum</subject><subject>Aluminum sulfate</subject><subject>Anaphylaxis</subject><subject>Animals</subject><subject>Antibody response</subject><subject>Antigens</subject><subject>Bioengineering</subject><subject>Biotechnology/Bioengineering</subject><subject>Cancer</subject><subject>Cancer vaccines</subject><subject>Cervical cancer</subject><subject>Cervix</subject><subject>Children</subject><subject>Dose-Response Relationship, Immunologic</subject><subject>Drug delivery systems</subject><subject>Drug dosages</subject><subject>Ear</subject><subject>Fear & phobias</subject><subject>Female</subject><subject>Health risks</subject><subject>Hostages</subject><subject>House mouse</subject><subject>Human papillomavirus</subject><subject>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18</subject><subject>Immunogenicity</subject><subject>Immunoglobulins</subject><subject>Infectious Diseases/Sexually Transmitted Diseases</subject><subject>Influenza</subject><subject>Injury prevention</subject><subject>Medical research</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Microscopy, Electron, Scanning</subject><subject>Models, Animal</subject><subject>Nanotechnology</subject><subject>Neutralizing</subject><subject>Papillomavirus</subject><subject>Papillomavirus Vaccines - administration & dosage</subject><subject>Projection</subject><subject>Risk reduction</subject><subject>Skin</subject><subject>Skin - immunology</subject><subject>Uterine Cervical Neoplasms - prevention & control</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Virology/Vaccines</subject><subject>Viruses</subject><subject>Women's Health/Gynecological Cancers</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk12L1DAUhoso7rr6D0QDguLFjPlok_ZGWBY_FhYWXPU2nKbpTMY0qUk7uhf-d1Onu8zIglJoD8lz3jTvOSfLnhK8JEyQNxs_Bgd22XunlxgTlnN8LzsmFaMLTjG7vxcfZY9i3GBcsJLzh9kRxZXghPHj7NfVN-PQFpQyDgbjHYIVGBcHpHTYGgUWKXApRhCjVwYG3aD12IFDPfTGWt_B1oQxoh9mWCNAzm-1RZ1RwS_64Dda7VRDgGuUjgLU-THq9G60fZw9aMFG_WT-nmRf3r_7fPZxcXH54fzs9GKhBGXDgjatoBVri7zMMSFlQVVDW0IqkVdENyIvypYrjXlb86qqOauLpqUCakV0TUXJTrLnO93e-ihn56IktKJJhJdVIs53RONhI_tgOgjX0oORfxZ8WEkIg1FWS9Ey2hRFlYsiz6GmQFPctA0USuSaTlpv59PGutON0m4IYA9ED3ecWcuV30paFZyzSeDVLBD891HHQXYmKm0tOJ3Mk6XIU2mr5M2_SMExJZgVk-aLv8i7bZipFaSbGtf69INq0pSnuWBlaiDBE7W8g0pPo1PhUz-2Jq0fJLw-SEjMoH8OKxhjlOdXn_6fvfx6yL7cY9ca7LCO3o5Ty8VDMN-BqS1jDLq9rQbBchqnGzfkNE5yHqeU9my_krdJN_PDfgPgXhug</recordid><startdate>20101018</startdate><enddate>20101018</enddate><creator>Corbett, Holly J</creator><creator>Fernando, Germain J P</creator><creator>Chen, Xianfeng</creator><creator>Frazer, Ian H</creator><creator>Kendall, Mark A F</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20101018</creationdate><title>Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model</title><author>Corbett, Holly J ; Fernando, Germain J P ; Chen, Xianfeng ; Frazer, Ian H ; Kendall, Mark A F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c723t-2df7293f5484011852cd2f1197491ed7458f6ce06fb699b63b5df27abc1eb2783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adjuvants</topic><topic>Alphapapillomavirus - immunology</topic><topic>Alum</topic><topic>Aluminum</topic><topic>Aluminum sulfate</topic><topic>Anaphylaxis</topic><topic>Animals</topic><topic>Antibody response</topic><topic>Antigens</topic><topic>Bioengineering</topic><topic>Biotechnology/Bioengineering</topic><topic>Cancer</topic><topic>Cancer vaccines</topic><topic>Cervical cancer</topic><topic>Cervix</topic><topic>Children</topic><topic>Dose-Response Relationship, Immunologic</topic><topic>Drug delivery systems</topic><topic>Drug dosages</topic><topic>Ear</topic><topic>Fear & phobias</topic><topic>Female</topic><topic>Health risks</topic><topic>Hostages</topic><topic>House mouse</topic><topic>Human papillomavirus</topic><topic>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18</topic><topic>Immunogenicity</topic><topic>Immunoglobulins</topic><topic>Infectious Diseases/Sexually Transmitted Diseases</topic><topic>Influenza</topic><topic>Injury prevention</topic><topic>Medical research</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Microscopy, Electron, Scanning</topic><topic>Models, Animal</topic><topic>Nanotechnology</topic><topic>Neutralizing</topic><topic>Papillomavirus</topic><topic>Papillomavirus Vaccines - administration & dosage</topic><topic>Projection</topic><topic>Risk reduction</topic><topic>Skin</topic><topic>Skin - immunology</topic><topic>Uterine Cervical Neoplasms - prevention & control</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Virology/Vaccines</topic><topic>Viruses</topic><topic>Women's Health/Gynecological Cancers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Corbett, Holly J</creatorcontrib><creatorcontrib>Fernando, Germain J P</creatorcontrib><creatorcontrib>Chen, Xianfeng</creatorcontrib><creatorcontrib>Frazer, Ian H</creatorcontrib><creatorcontrib>Kendall, Mark A F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Corbett, Holly J</au><au>Fernando, Germain J P</au><au>Chen, Xianfeng</au><au>Frazer, Ian H</au><au>Kendall, Mark A F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2010-10-18</date><risdate>2010</risdate><volume>5</volume><issue>10</issue><spage>e13460</spage><epage>e13460</epage><pages>e13460-e13460</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Better delivery systems are needed for routinely used vaccines, to improve vaccine uptake. Many vaccines contain alum or alum based adjuvants. Here we investigate a novel dry-coated densely-packed micro-projection array skin patch (Nanopatch™) as an alternate delivery system to intramuscular injection for delivering an alum adjuvanted human papillomavirus (HPV) vaccine (Gardasil®) commonly used as a prophylactic vaccine against cervical cancer.
Micro-projection arrays dry-coated with vaccine material (Gardasil®) delivered to C57BL/6 mouse ear skin released vaccine within 5 minutes. To assess vaccine immunogenicity, doses of corresponding to HPV-16 component of the vaccine between 0.43 ± 0.084 ng and 300 ± 120 ng (mean ± SD) were administered to mice at day 0 and day 14. A dose of 55 ± 6.0 ng delivered intracutaneously by micro-projection array was sufficient to produce a maximal virus neutralizing serum antibody response at day 28 post vaccination. Neutralizing antibody titres were sustained out to 16 weeks post vaccination, and, for comparable doses of vaccine, somewhat higher titres were observed with intracutaneous patch delivery than with intramuscular delivery with the needle and syringe at this time point.
Use of dry micro-projection arrays (Nanopatch™) has the potential to overcome the need for a vaccine cold chain for common vaccines currently delivered by needle and syringe, and to reduce risk of needle-stick injury and vaccine avoidance due to the fear of the needle especially among children.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>20976136</pmid><doi>10.1371/journal.pone.0013460</doi><tpages>e13460</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2010-10, Vol.5 (10), p.e13460-e13460 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1292197689 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Adjuvants Alphapapillomavirus - immunology Alum Aluminum Aluminum sulfate Anaphylaxis Animals Antibody response Antigens Bioengineering Biotechnology/Bioengineering Cancer Cancer vaccines Cervical cancer Cervix Children Dose-Response Relationship, Immunologic Drug delivery systems Drug dosages Ear Fear & phobias Female Health risks Hostages House mouse Human papillomavirus Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 Immunogenicity Immunoglobulins Infectious Diseases/Sexually Transmitted Diseases Influenza Injury prevention Medical research Mice Mice, Inbred C57BL Microscopy, Electron, Scanning Models, Animal Nanotechnology Neutralizing Papillomavirus Papillomavirus Vaccines - administration & dosage Projection Risk reduction Skin Skin - immunology Uterine Cervical Neoplasms - prevention & control Vaccination Vaccines Virology/Vaccines Viruses Women's Health/Gynecological Cancers |
| title | Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T21%3A36%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Skin%20vaccination%20against%20cervical%20cancer%20associated%20human%20papillomavirus%20with%20a%20novel%20micro-projection%20array%20in%20a%20mouse%20model&rft.jtitle=PloS%20one&rft.au=Corbett,%20Holly%20J&rft.date=2010-10-18&rft.volume=5&rft.issue=10&rft.spage=e13460&rft.epage=e13460&rft.pages=e13460-e13460&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0013460&rft_dat=%3Cgale_plos_%3EA473853876%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1292197689&rft_id=info:pmid/20976136&rft_galeid=A473853876&rft_doaj_id=oai_doaj_org_article_7f32d55947544ab2a2594dfda5c74e29&rfr_iscdi=true |